Ketamine Therapy for Anxiety: Does It Work?

Ketamine may reduce anxiety symptoms, sometimes within hours, but how much that finding means depends entirely on which kind of anxiety you're asking about. The research is far stronger for depression than for anxiety disorders themselves.

A handful of small studies have enrolled people specifically because they had treatment-resistant generalized anxiety disorder or social anxiety disorder, and those studies reported real improvement. Much of the larger body of evidence is different: it comes from people treated for depression, where anxiety was measured as a secondary symptom rather than the target.

Using ketamine or Spravato specifically to treat an anxiety disorder is off-label, and the honest summary is that the signal is genuine and the evidence base is small. That's enough for some clinicians to consider it in treatment-resistant cases. It isn't enough to call ketamine an established treatment for anxiety disorders.

Anxiety Symptoms and Anxiety Disorders Aren't the Same Thing

This distinction runs through the entire literature, and missing it is how "ketamine treats anxiety" ends up on clinic websites.

Someone with treatment-resistant depression often carries worry, tension, agitation, and anxious distress alongside low mood. If those symptoms fall during depression treatment, that's clinically meaningful and worth knowing. It is not the same evidence as enrolling people whose primary diagnosis is generalized anxiety disorder and testing whether ketamine treats that condition.

The first tells you anxiety scores moved in people being treated for something else. The second tells you whether the drug treats the disorder. When you read that a study "found reduced anxiety," the useful question is which of those two things happened.

What Does the Research Overall Show?

Both kinds of study exist, and they point in a similar direction with very different confidence.

A transdiagnostic meta-analysis pooled 14 randomized trials measuring anxiety, with 11 contributing to the quantitative analysis. Participants mostly had PTSD or mood disorders, with only two studies in anxiety disorders. Ketamine beat placebo on anxiety at every timepoint, strongly in the first hours and more modestly at one to two weeks. Nine of the eleven studies carried a high risk of bias.

A separate review restricted itself to randomized trials in primary anxiety spectrum disorders and found only six: two in social anxiety disorder, three in PTSD, and one in OCD. Generalized anxiety data were too sparse to pool at all. Four of the six trials had fewer than 20 participants.

A 2026 systematic review puts the imbalance in sharp relief. Of 78 studies meeting its criteria, 11 investigated ketamine in people whose primary problem was a DSM-5 anxiety disorder. The other 67 involved depression: 55 treated unipolar or bipolar depression and assessed anxiety symptoms secondarily, and 12 compared anxious with non-anxious treatment-resistant depression.

That review found reductions in anxiety in both settings, with effects appearing more sustained under repeated or maintenance treatment, and symptoms able to re-emerge once maintenance ends. The studies were notably heterogeneous, spanning subcutaneous, intravenous, intramuscular, and oral ketamine. Its authors still called the evidence preliminary and in need of confirmation.

That's the honest shape of the field. Consistent signal, small and fragile evidence.

Ketamine for Generalized Anxiety Disorder

Direct evidence in generalized anxiety disorder comes mainly from small studies that often enrolled people with either refractory GAD or social anxiety disorder, rather than GAD alone.

A 2017 study enrolled 12 patients with treatment-refractory GAD, social anxiety disorder, or both, none of whom were currently depressed. That last detail matters, because it isolates anxiety from depression treatment. They received ascending single doses of subcutaneous ketamine, 0.25, 0.5, and 1 mg/kg at weekly intervals. Anxiety improved within about an hour and persisted up to seven days, following a dose-response pattern.

A separate 2020 study from the same group was the controlled one. It was an exploratory double-blind replication in 12 patients with treatment-resistant GAD and social anxiety disorder, again not currently depressed, using the same ascending subcutaneous doses. Midazolam at 0.01 mg/kg served as a psychoactive control, randomly inserted into the dose sequence. Improvement again appeared within about an hour, lasted up to a week, and followed a dose-response pattern.

Twelve patients each, by the authors' own description exploratory. A broader review of refractory anxiety found 18 studies covering GAD and social anxiety, ranging from 2 to 209 participants, with designs too varied to combine.

No large randomized trial has tested ketamine in generalized anxiety disorder. Until one does, this remains preliminary.

Ketamine for Social Anxiety Disorder

Social anxiety has the best-designed study in this area, and it's still small.

Eighteen adults with social anxiety disorder received IV ketamine at 0.5 mg/kg and saline placebo in random order, separated by a 28-day washout, in a double-blind crossover trial. Blinded raters using the Liebowitz Social Anxiety Scale found significantly greater improvement after ketamine than placebo.

The self-rated measure is where it gets complicated. Continuous VAS-Anxiety scores showed no significant treatment effect over time, although a separate predefined response analysis did favor ketamine. More than half of participants also met that VAS response definition after placebo, which makes it harder to interpret. Mixed outcome measures like these are a reason for caution.

Eighteen people in a crossover design is a starting point, not an established treatment. Ketamine isn't a proven therapy for social anxiety disorder.

What About Panic Disorder?

Direct evidence for panic disorder is currently very limited.

Direct published evidence evaluating ketamine for panic disorder is very limited, and I could not identify a published controlled trial establishing efficacy for it. The systematic review of refractory anxiety covering 18 studies focused on generalized and social anxiety, and panic disorder wasn't specifically addressed. A completed trial in adolescents enrolled several treatment-resistant anxiety disorders including panic disorder, which is not the same as demonstrating efficacy for panic disorder.

It would be easy to argue that a drug helping generalized and social anxiety should also help panic, and that argument isn't evidence. Panic disorder has its own biology, treatment response patterns, and established therapies. Anyone presenting ketamine as a panic disorder treatment is extrapolating.

What If Anxiety Happens Alongside Depression?

This is where most of the data actually lives, and it deserves care.

People with treatment-resistant depression frequently have prominent anxiety, and studies in that population consistently report anxiety scores improving alongside mood. That's clinically useful. If your anxiety is bound up with a depressive episode, treating the depression may well ease it, and our guide on ketamine therapy for depression covers that evidence.

What's less clear is whether ketamine has a separate anti-anxiety action. The transdiagnostic meta-analysis found anxiety and depression improvements correlated at both the 24-hour and one-to-two-week marks. So the larger literature shows anxiety often improves, but because the two track together in many studies, it's hard to know how much reflects an independent anti-anxiety effect.

Some reviewers have argued the opposite, suggesting an anxiolytic effect distinct from the antidepressant one. The disagreement is unresolved, and it's the reason the overall anxiety evidence looks larger than the primary anxiety disorder evidence.

How Quickly Can Anxiety Improve?

Fast, in the studies that measured it, though speed varies by person.

In the refractory GAD and social anxiety work, patients reported reduced anxiety within about an hour of dosing. The transdiagnostic pooled analysis found its largest effect in the first 12 hours, shrinking by 24 hours and shrinking further by one to two weeks.

Two cautions. These are small studies reporting group averages, so individual responses ranged from substantial to none at all. And rapid onset says nothing about durability, which is a separate question with a less encouraging answer.

How Long Can the Anti-Anxiety Effect Last?

After a single dose, roughly a week is the pattern in the direct anxiety studies.

Anxiolytic effects appeared within an hour and lasted up to about seven days, with symptoms generally returning to baseline around two weeks. The social anxiety crossover trial followed people for 14 days and found some maintained lower anxiety across that window, though not all did.

This is where anxiety evidence and depression evidence part company. Multi-year maintenance data exist for esketamine in depression, and nothing comparable exists for anxiety disorders. Our guide on the long-term effects of ketamine therapy covers what those longer datasets do and don't establish.

Does Repeated Ketamine Treatment Work Better Than a Single Treatment?

Probably, based on limited evidence, and the specifics matter less than people assume.

One study gave once or twice weekly subcutaneous ketamine at 1 mg/kg for three months to people with refractory generalized and social anxiety. Anxiety stayed reduced across 14 weeks, and dissociative side effects lessened over time. Most participants reported anxiety returning once treatment ended.

Read that as a study protocol, not a prescription. The six-infusion series commonly used for depression was developed for depression, and borrowing it wholesale for anxiety isn't evidence-based scheduling. No trial has established an optimal frequency, duration, or dose for anxiety disorders.

Is Ketamine FDA Approved for Anxiety?

No, in any form.

Generic ketamine injection is approved as an anesthetic. Its psychiatric use, including for anxiety, is off-label. Spravato has FDA-approved indications in depression, not in anxiety disorders.

Off-label isn't a synonym for improper. Clinicians may legally prescribe an approved medication outside its labeled use when they judge it medically appropriate, and this happens routinely across medicine. What off-label does mean is that no regulator has reviewed evidence for this specific use, so the burden of judging the evidence falls on you and your clinician.

What About Spravato for Anxiety?

Spravato's approved indications are treatment-resistant depression, and depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. Anxiety disorders aren't among them.

Depression trials involving Spravato have included people with anxious symptoms, and anxiety measures can improve in that setting. That's a finding about depressed patients, not evidence that esketamine treats generalized anxiety disorder or social anxiety disorder.

The 2026 systematic review is useful here. Among its 11 studies of people whose primary problem was an anxiety disorder, it found no esketamine study at all. Direct primary-anxiety research is effectively ketamine research, not a Spravato evidence base. Esketamine has been studied in depression populations where anxiety symptoms were assessed, which is a different question. It's also worth not assuming the IV and subcutaneous findings above transfer to a different molecule given by a different route. Our guide comparing IV ketamine and Spravato explains why the two aren't interchangeable.

Why Might Ketamine Affect Anxiety?

Ketamine acts on the glutamate system through NMDA receptor blockade and downstream AMPA signaling, and that pharmacology is well established. Our guide on what ketamine therapy is covers the mechanism in more depth.

What connects that pharmacology to anxiety specifically is proposed rather than demonstrated. Researchers have pointed toward effects on neuroplasticity and on fear and threat processing circuits, and toward the possibility that rigid patterns of worry become more changeable. These are plausible hypotheses under investigation, not established explanations.

Who Has Actually Been Studied?

The people in these studies are a narrow group, which matters when deciding whether the findings apply to you.

They were adults, generally with anxiety that had already failed standard treatments. Some were specifically screened to exclude current depression, which is what makes those results informative about anxiety on its own. Others were being treated for depression and happened to have anxiety measured.

Children and adolescents haven't been studied here. Neither have most people with straightforward, previously untreated anxiety, because these trials recruited refractory cases. Total participant numbers across the direct anxiety literature run in the hundreds, not thousands.

What Are the Biggest Limitations in the Evidence?

The gaps are specific and worth naming.

Direct GAD and social anxiety trials are tiny, several with fewer than 20 people
Follow-up is usually days to weeks, rarely months
Anxiety is a secondary outcome in much of the research
Studies used different routes, doses, and rating scales, which makes pooling difficult
Ketamine's noticeable psychoactive effects make blinding hard, so participants often guess their assignment
Panic disorder has essentially no direct trial evidence
Almost no head-to-head comparisons exist against established anxiety treatments
Nobody can currently predict who will respond
Most studies carry a high risk of bias by the reviewers' own assessment

How Does Ketamine Compare With Standard Anxiety Treatments?

It doesn't compete on evidence, and that's the key point.

Established first-line care for anxiety disorders includes evidence-based psychotherapy matched to the specific disorder, and medications such as SSRIs and SNRIs where a clinician judges them appropriate. Those approaches rest on large randomized trials, long follow-up, and professional guidelines built over decades.

Ketamine's anxiety evidence is a few hundred participants across mostly small studies. For someone whose anxiety hasn't responded to established treatments, some clinicians consider it. That's a different proposition from a first-line option, and no current guideline positions it as one.

What Should You Ask a Ketamine Provider About Anxiety Treatment?

Are you treating a primary anxiety disorder, or anxiety symptoms tied to depression?
What evidence supports using ketamine for my specific diagnosis?
Is this off-label, and how do you explain that to patients?
Which route are you recommending, and why that one?
How will we measure whether my anxiety is actually improving?
How many treatments before we decide it isn't working?
How does this fit alongside my current therapy and medications?

That last question matters if you take a benzodiazepine, as many people with anxiety do. Bring it up with your provider rather than adjusting anything yourself, and our guide on ketamine and other medications explains why the combination gets attention.

Finding a Provider for Ketamine Treatment

The provider you want is the one who slows down before treating.

That means diagnosing carefully rather than treating "anxiety" as a single condition. It also means being straightforward that the use is off-label, describing the actual evidence including its size, and measuring symptoms with real scales. It also means reviewing your existing treatments and setting criteria upfront for continuing or stopping.

A provider who tells you ketamine reliably treats anxiety is ahead of the research. Our guides on how to choose a ketamine clinic and who is a good candidate for ketamine therapy cover the screening questions in more detail. You can also search ketamine clinics near you or browse IV ketamine infusion clinics.